BioMark’s Quebec Laboratory Begins To Take Shape

biomark diagnostics qtrap 6500 mass spectrometer

BioMark Diagnostics is pleased to announce that the installation of its Quebec laboratory is now underway. With the installation of the Sciex QTrap 6500+ high performance mass spectrometer, BioMark is on target with its plan to build an optimal laboratory infrastructure that will serve as the gold-standard for world-class cancer detection and research. Dr. Jeff […]

BIOMARK RECEIVES $825K GRANT TO DEVELOP ITS LIQUID BIOPSY ASSAY FOR LUNG CANCER SCREENING

Vancouver, British Columbia – (June 1st, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce today that its wholly-owned subsidiary BioMark Diagnostic Solutions Inc. (“BDS”) received funding to develop an early-stage lung cancer screening assay using BioMark’s proprietary liquid biopsy platform. The total sponsored research grant is about […]

BIOMARK REÇOIT UNE SUBVENTION DE 825 K $ POUR DÉVELOPPER SON TEST DE BIOPSIE LIQUIDE POUR LE DÉPISTAGE DU CANCER DU POUMON

Vancouver, Colombie-Britannique – (1er juin 2021) – BioMark Diagnostics Inc. («BioMark») (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) est heureuse d’annoncer aujourd’hui que sa filiale en propriété exclusive BioMark Diagnostic Solutions Inc. (“BDS”) a reçu un financement pour le développement d’un test de dépistage du cancer du poumon à un stade précoce en utilisant la technologie […]

BIOMARK ANNOUNCES CHANGE OF AUDITOR

Vancouver, British Columbia – (May 31, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) announces that it has changed its auditors from Manning Elliott LLP (“Former Auditor”) to PricewaterhouseCoopers LLP (“Successor Auditor”).  The Former Auditor resigned as the auditor of the Company effective May 17th, 2021 and the board of directors […]

Liquid Biopsy – What Is It?

biomark diagnostics liquid biopsy test tubes with dna blood samples

A liquid biopsy is a test that is  performed on a sample of blood taken from a patient. The test analyzes the blood sample and looks for traces of cancer DNA from tumor cells that are often present in the blood.  Multiple blood samples over a period of time allow physicians and doctors to examine […]

10 Reasons why Biomark BUX is a Buy and Long-term Hold

buy-hold-10-reasons-biomark-stock

The article presented on this page may contain forward-looking statements. These statements relate to future events or future financial performance. Any statements that are not statements of historical fact (including without limitation statements to the effect that the Company or its management “believes”, “expects”, “anticipates”, “plans”, and similar statements) should be considered forward looking statements. […]

BioMark Diagnostics and Phytronix Technologies Strategic Technology Integration Partnership

biomark diagnostics phytronix partnership

The Right Leadership and Technology Partnerships designed to deliver clinical solutions to cancer care management. Dr. Haince bring solid capabilities in clinical development and commercialization of cancer diagnostic tests in N. America, Accreditation and core lab management expertise, scientific rigour and business development capabilities to BioMark as GM and CSO (Chief Scientist Officer). At Diagnocure, […]

BIOMARK TO OPEN A DIAGNOSTIC LABORATORY IN QUÉBEC

BioMark Lab in Quebec

Vancouver, British Columbia – (April 29, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce today that its wholly-owned subsidiary BioMark Diagnostic Solutions Inc. (“BDS”) will be operating a diagnostic laboratory in Quebec, Canada, which will primarily serve to advance the clinical validation of its proprietary liquid biopsy […]

BIOMARK ANNOUNCES EXERCISE OF WARRANTS AND GAIN DTC ELIGIBILITY FOR ITS COMMON SHARES

biomark announces exercise of warrants and gain dtc eligibility for its common shares

Vancouver, British Columbia – (April 21, 2021) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce today the agreement by several long-time strategic accredited investors and insiders to exercise approximately 2,000,000 warrants issued in connection with the Company’s private placement of units completed in April 2019, with the warrant […]